drugset
drugset / Trial / NCT05675072

Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

NCT05675072 ↗

Phase 2/3 Unknown 1336 enrolled Frontier Biotechnologies Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19). A total of about 1336 subjects are planned to be enrolled. The subjects will be randomized in a 1:1 ratio to FB2001 group or placebo group while both receiving standard of care treatment.

Timeline

Start
2023-01-04
Primary completion
2023-09
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject FB2001 Small molecule — Inhaled

Indications

No indication recorded.